Form 4: Gabrielle Sulzberger Reports Acquisition of Eli Lilly & Co Stock

Director Gabrielle Sulzberger acquired 6.566 shares of Eli Lilly & Co common stock at $755.11 per share on May 19, 2025, through the Lilly Directors' Deferral Plan.

Summary

• On May 19, 2025, Gabrielle Sulzberger, a director of Eli Lilly & Co, acquired 6.566 shares of common stock.
• The acquisition was made at a price of $755.11 per share.
• These shares were acquired through the Lilly Directors' Deferral Plan in lieu of cash compensation.
• Following the transaction, Sulzberger beneficially owns 2,568.651 shares of Eli Lilly & Co.
• The acquired shares are deferred as stock units and will be settled in shares of common stock after Sulzberger's separation from service.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a routine transaction. It's neither particularly positive nor negative from an investment perspective.

Positives

• The acquisition reflects a director's continued investment in the company.
• The use of the Lilly Directors' Deferral Plan allows for tax-deferred accumulation of company stock.

Future Outlook

The acquired shares will be settled in the future upon the reporting person's separation from service.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. These filings provide transparency to the market regarding insider activity.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider trading activity.
• The director's investment may signal confidence in the company's future performance.

Key Dates

Keywords

Eli Lilly & Co, Director, Stock Acquisition, Form 4, Sulzberger, LLY, Directors' Deferral Plan, Beneficial Ownership